These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1922575)

  • 1. Prognostic value of the epithelial membrane antigen (EMA) in the case of Hodgkin's disease.
    Touhami H; Sotto JJ; Sotto MF; Couderc P; Keddari E; Brahimi S; Kubisz P
    Neoplasma; 1991; 38(4):433-7. PubMed ID: 1922575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pleural effusion in Hodgkin's lymphoma. Report of a case with immunoperoxidase studies.
    Peterson IM; Raible M
    Acta Cytol; 1991; 35(3):300-5. PubMed ID: 1710403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of phenotyping by Ber-H2, Leu-M1, EMA in Hodgkin's disease.
    de Mascarel I; Trojani M; Eghbali H; Coindre JM; Bonichon F
    Arch Pathol Lab Med; 1990 Sep; 114(9):953-5. PubMed ID: 1975165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?].
    Kanaev SV; Girshovich MM; Golovanov SG; Gershanovich ML
    Vopr Onkol; 2007; 53(4):453-5. PubMed ID: 17969410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of combined treatment of stage III(B) Hodgkin's disease].
    Kanaev SV; Golovanov SG; Girshovich MM; Gershanovich ML
    Vopr Onkol; 2006; 52(5):525-30. PubMed ID: 17168360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
    Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
    Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
    Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
    Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study.
    Leoncini L; Del Vecchio MT; Kraft R; Megha T; Barbini P; Cevenini G; Poggi S; Pileri S; Tosi P; Cottier H
    Am J Pathol; 1990 Nov; 137(5):1047-57. PubMed ID: 2173409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
    Koontz BF; Kirkpatrick JP; Clough RW; Prosnitz RG; Gockerman JP; Moore JO; Prosnitz LR
    J Clin Oncol; 2006 Feb; 24(4):605-11. PubMed ID: 16446333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease].
    Kanaev SV; Gershanovich ML; Pozharisskiĭ KM; Girshovich MM; Malinin AP; Golovanov SG
    Vopr Onkol; 2004; 50(6):652-7. PubMed ID: 15755057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma.
    Yahalom J
    J Clin Oncol; 2006 Feb; 24(4):544-8. PubMed ID: 16446326
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
    Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
    Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
    Kuleva SA
    Vopr Onkol; 2008; 54(6):768-70. PubMed ID: 19241857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.